Policy shift needed to boost biosimilar uptake: Halton

Boosting uptake of biosimilars will require practitioner change and a policy rethink, GBMA chair says  Australia is “underdone on penetration in the market” when it comes to uptake of biosimilar medications, Generic and Biosimilar Medicines Association (GBMA) chair, Jane Halton says.   Speaking during the State of the Industry panel discussion at the Australian Pharmacy Profession